Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Head and Neck Tumors Clinical Trial

Official title:

A Prospective Single-center, Single-arm Clinical Study of the PD-1 Inhibitor Tislelizumab Combined With APF Sequential Surgery or Radical Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05758389
• Other study ID #: 2021-666-02
• Status: Recruiting
• Phase: Phase 2
• Start date: March 7, 2023
• Est. completion date: June 7, 2025

Study information

• Verified date: January 2024
• Source: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Contact: Jing Yan
• Phone: +86 15805182426
• Email: firefreebird[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are:

1. evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck tumors.

2. the exploration of efficacy-related immune microenvironment genes Participants will receive tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 29
• Est. completion date: June 7, 2025
• Est. primary completion date: June 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 years old;

2. Histological or cytology-confirmed head and neck tumors (including oral, oropharynx, hypopharynx, larynx) squamous cell carcinoma, etc.;

3. Have at least one radiographically measurable lesion (RECIST 1.1 criteria);

4. The clinical stage is III-IVb (P16-) or II-III (P16+);

5. There are tumor samples that can detect gene expression;

6. ECOG score 0-1 points;

7. Have not received radiotherapy and chemotherapy or other anti-tumor drugs before;

8. The following hematological indicators need to be met: (1) Neutrophil count= 1.5×109/L; (2) Hemoglobin= 10g/dL; (3) Platelet count = 100×109/L

9. The following biochemical indicators need to be met: (1) Total bilirubin =1.5× upper limit of normal value (ULN); (2) AST and ALT < 1.5 ×ULN; (3) Creatinine clearance = 60ml/min; (4) Alkaline phosphatase = 5 times ULN; (5) Activated partial thromboplastin time (APTT) and international normalized ratio (INR) =1.5xULN (for anticoagulation at a stable dose such as low molecular weight heparin or warfar.) LIN and INR can be screened within the expected therapeutic range of anticoagulants)

10. Subjects of childbearing age need to take appropriate protective measures (contraceptive measures) before enrollment and in trials administration or other methods of birth control);

11. Have signed informed consent;

12. Ability to follow study protocols and follow-up procedures.

Exclusion Criteria:

1. Received anti-tumor treatment in the past 6 months, including radiotherapy and chemotherapy, surgery, immunotherapy Wait;

2. Previously or concurrently suffering from other malignant tumors (except for malignant tumors that have been cured and survived for more than 5 years without cancer, such as skin basal cell carcinoma, cervical carcinoma in situ, superficial bladder cancer, and thyroid papillary carcinoma, etc.);

3. There is distant metastasis;

4. Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); but excludes autoimmune-mediated hypothyroidism on stable doses of thyroid replacement hormone; type 1 diabetes on stable doses of insulin; vitiligo or resolved childhood asthma/allergies, Patients who do not require any intervention after adulthood;

5. Known history of primary immunodeficiency (including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation);

6. Severe infection (CTC AE>2 grade) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc.; baseline chest imaging examination showed active lung Inflammation, symptoms and signs of infection within 2 weeks before the first use of the study drug or the need for oral or intravenous antibiotic treatment (excluding prophylactic use of antibiotics);

7. The subject has severe liver and kidney dysfunction, HIV infection, HCV infection, uncontrolled clinical symptoms or diseases of the heart, such as: heart failure above NYHA grade II or echocardiography showing left ventricular ejection fraction (LVEF) < 50%; unstable angina; myocardial infarction within 1 year; patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention (including QTc interval = 470 ms); uncontrolled diabetes, uncontrolled Patients with high blood pressure, hypertensive crisis or hypertensive encephalopathy or other diseases considered by the researchers to be ineligible;

8. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/ml, or patients with active hepatitis C virus (HCV) should be excluded; inactive hepatitis B surface Antigen carriers, treated and stable hepatitis B patients (HBV DNA<500IU/ml), and cured hepatitis C patients can be enrolled;

9. Have a history of interstitial lung disease (excluding radiation pneumonitis that has not been treated with hormones) and non-infectious pneumonia;

10. Active tuberculosis infection was found through medical history or CT examination, or patients with a history of active tuberculosis infection within 1 year before enrollment, or patients with a history of active tuberculosis infection more than 1 year ago but without formal treatment;

11. Patients who have received any of the following treatments (1) Subjects who need to be given corticosteroids (> 10 mg prednisone equivalent dose per day) or other immunosuppressants for systemic treatment within 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergies and nausea, Cases of use of corticosteroids for vomiting. In the absence of active autoimmune disease, corticosteroid replacement with inhaled or topical steroids and curative doses of prednisone >10 mg/day is permitted; (2) Have been vaccinated against tumors; those who have been vaccinated or have been vaccinated with live vaccines within 4 weeks before the first administration of the study drug; (3) Received major surgery or severe trauma within 4 weeks before the first use of the study drug; (4) Enrolled in another clinical study at the same time;

12. Pregnant and lactating women. Women of childbearing age must take a pregnancy test within 7 days before enrollment Negative;

13. Substance abuse, clinical or psychological or social factors that hinder informed consent or research conduct influences;

14. Those who may be allergic to the study drug;

15. Those who cannot perform radiotherapy and chemotherapy due to social or geographical factors;

16. Significant weight loss within 6 weeks before enrollment (weight loss = 10%);

17. Any uncertain factors affecting the safety or compliance of the subjects;

18. Contraindications to hormone use.

Related Conditions & MeSH terms

• Head and Neck Neoplasms
• Head and Neck Tumors

Intervention

Drug:
• Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU
evaluate the efficacy and safety of immunotherapy combined with chemotherapy

Locations

Country	Name	City	State
China	Department of Oncology, Drum Tower Hospital, Nanjing University School of Medicine	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of pathological examination	Changes in pathologic examination before treatment and after 3-cycle induction therapy were evaluated to derive the number and proportion of patients with pathological complete remission	Change from Baseline pathologic examination at the end of Cycle 3 (each cycle is 21 days)
Primary	Change of tumor size	imaging (MRI or CT) assessment according to RECIST v1.1 was performed and documented during follow-up as required	Change from baseline tumor size at the end of Cycle 3 (each cycle is 21 days)
Secondary	Security assessment	according to the NCI-CTCAE 4.0 adverse reaction evaluation criteria	At the end of Cycle 3 (each cycle is 21 days)